Compare Novo Nordisk A/S (NVO) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.9. The key difference: Novo Nordisk A/S pays a 3.63% dividend while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| NVO | SJNK | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Sector/Thematic |
52-Week High | $71.70 | $25.63 |
52-Week Low | $35.29 | $24.75 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
